BidaskClub upgraded shares of Agenus (NASDAQ:AGEN) from a buy rating to a strong-buy rating in a report published on Wednesday.
AGEN has been the subject of several other reports. Zacks Investment Research upgraded Agenus from a hold rating to a buy rating and set a $4.50 price target for the company in a research note on Tuesday, January 9th. ValuEngine upgraded Agenus from a sell rating to a hold rating in a research note on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Agenus presently has a consensus rating of Buy and an average target price of $5.81.
Agenus (NASDAQ AGEN) traded down $0.12 on Wednesday, reaching $5.75. The company had a trading volume of 2,056,973 shares, compared to its average volume of 1,891,631. The company has a market cap of $598.54, a P/E ratio of -4.91 and a beta of 1.50. Agenus has a twelve month low of $3.20 and a twelve month high of $6.19. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in shares of Agenus by 1.2% during the 4th quarter. BlackRock Inc. now owns 4,883,221 shares of the biotechnology company’s stock valued at $15,920,000 after acquiring an additional 55,759 shares during the period. RTW Investments LP lifted its position in shares of Agenus by 2.6% during the 4th quarter. RTW Investments LP now owns 4,329,816 shares of the biotechnology company’s stock valued at $14,115,000 after acquiring an additional 111,296 shares during the period. Vanguard Group Inc. lifted its position in shares of Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after acquiring an additional 174,162 shares during the period. Artal Group S.A. lifted its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after acquiring an additional 500,000 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Agenus by 4.1% during the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after acquiring an additional 37,239 shares during the period. Hedge funds and other institutional investors own 36.69% of the company’s stock.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.